Treatment to Prevention Task Force
Sandrine Andrieu, MD, PhD
Dr. Sandrine Andrieu is a professor of public health and Chair of the Clinical Epidemiology and Public Health Department at Toulouse University Hospital. She leads the aging research team at the Center for Epidemiology and Research in Population Health (CERPOP) and has published over 300 works on aging and Alzheimer’s disease. Dr. Andrieu specializes in Alzheimer’s prevention, age-related functional prevention, and healthy aging. She is actively involved in major European studies and serves as the scientific committee president for France Alzheimer.
Karen Bell, MD
Dr. Karen Bell, Professor of Neurology at Columbia University Medical Center, in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the GH Sergievsky Center, specializes in neurodegenerative cognitive disorders. As Director of the Education Core at Columbia's Alzheimer's Disease Research Center, she develops physician and community education programs. Dr. Bell is active in professional organizations, serves on multiple advisory boards, and mentors students through the Harlem Children Society.
Adam Boxer, MD, PhD
Dr. Adam L. Boxer, Endowed Professor in Memory and Aging at the University of California, San Francisco, directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program. He serves as the Principal Investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium and has led major studies including the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI).
Maria Carrillo, MD
Dr. Maria Carrillo, Chief Science Officer of the Alzheimer's Association, leads the world’s largest nonprofit research program for Alzheimer’s and dementia. She oversees global initiatives, including the Alzheimer's Association International Conference (AAIC) and is a co-principal investigator for the Alzheimer's Network for Treatment and Diagnostics, tracking outcomes of FDA-approved therapies. An internationally recognized expert, Dr. Carrillo has received numerous awards for advancing Alzheimer’s clinical trials and serves on prominent boards in the field.
Suzanne Craft, PhD
Dr. Suzanne Craft is a Professor of Medicine at Wake Forest School of Medicine and is the Founding Director of the NIA-funded Alzheimer’s Disease Research Center. Her research focuses on metabolic disorders in Alzheimer’s development, leading innovative clinical trials on treatments such as intranasal insulin and dietary intervention. Craft is a recipient of the National Institute of Health MERIT Award and the Alzheimer’s Association Zenith Award. She has served on prestigious advisory groups, including the NIA Board of Scientific Counselors and the Alzheimer’s Clinical Trial Consortium (ACTC).
Jeffrey Cummings, MD, ScD
Dr. Jeffrey L. Cummings, a renowned Alzheimer’s researcher and clinical trial leader, is a research professor at the University of Nevada, Las Vegas Department of Brain Health. Previously, he founded the Cleveland Clinic Lou Ruvo Center for Brain Health and directed Alzheimer’s research centers at the University of California, Los Angeles. Ranked among the top Alzheimer’s scientists globally, Dr. Cummings focuses on embracing clinical trials, developing therapies for brain diseases, and the interface of neuroscience and society. He has received numerous awards, including the Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award and the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award. He also serves as Director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.
Bonnie Davis, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et feugiat turpis. Nulla et ultricies mauris, auctor consequat libero. Nulla lacus nulla, laoreet et commodo auctor, faucibus at mauris. Mauris mauris turpis, sagittis eget eros et, dictum pharetra turpis. Mauris pellentesque, quam quis scelerisque fringilla, velit lorem consectetur libero, ac malesuada ante lacus sit amet leo. Integer rutrum, nisl eget suscipit porta, nisi dolor ullamcorper ligula, quis tincidunt nisi nunc a urna. Ut eu vestibulum sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Phyllis Barkman Ferrell, DrPH MBA
Phyllis Ferrell is a global leader in brain health and longevity innovation. After three decades at Eli Lilly & Company, where she advanced Alzheimer’s therapeutics and diagnostics, she now advises organizations to transform health systems worldwide. As Chief Impact Officer for StartUp Health Alzheimer’s Moonshot, she champions innovation in Alzheimer’s care. Ferrell also supports global initiatives like the Davos Alzheimer’s Collaborative to prepare healthcare systems for aging populations. She holds leadership roles in numerous health and advocacy organizations and is passionate about improving brain health to support future generations.
Lawrence Honig, MD
Dr. Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center, is a renowned expert in neurodegenerative diseases, including Alzheimer’s disease, Lewy Body Dementia, Frontotemporal Degeneration, and Progressive Supranuclear Palsy. He directs the New York State Center of Excellence for Alzheimer’s Disease and co-directs the Lewy Body Disease Research Center of Excellence and the Progressive Supranuclear Palsy Center of Care. With board certifications in Behavioral Neurology, Neuropsychiatry, and Geriatric Neurology, Dr. Honig combines clinical expertise with groundbreaking research. He serves as a principal investigator for observational studies and clinical drug trials focused on advancing treatments for neurodegenerative conditions. A member of Columbia's faculty since 2000, he has made significant contributions to understanding and addressing disorders of nervous system aging and degeneration.
Takeshi Iwatsubo, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et feugiat turpis. Nulla et ultricies mauris, auctor consequat libero. Nulla lacus nulla, laoreet et commodo auctor, faucibus at mauris. Mauris mauris turpis, sagittis eget eros et, dictum pharetra turpis. Mauris pellentesque, quam quis scelerisque fringilla, velit lorem consectetur libero, ac malesuada ante lacus sit amet leo. Integer rutrum, nisl eget suscipit porta, nisi dolor ullamcorper ligula, quis tincidunt nisi nunc a urna. Ut eu vestibulum sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Nancy Lynn Keach
Nancy Lynn Keach, Senior Vice President of Strategic Partnerships at BrightFocus Foundation, facilitates partnerships to advance research and awareness for Alzheimer’s, Macular Degeneration, and Glaucoma. She has worked on the acclaimed film Glen Campbell…I’ll Be Me and is Executive Producer for Turning Point, a documentary on Alzheimer’s research. Formerly Executive Director and Chief Operating Officer at the Alzheimer’s Drug Discovery Foundation, Lynn has also held leadership roles at the Arnold P. Gold Foundation for Humanism in Medicine and the American Museum of Natural History in New York. She is a founding member of WomenAgainstAlzheimer’s.
Doris Molina-Henry, PhD
Doris Molina-Henry is an Assistant Professor at the USC Keck School of Medicine Alzheimer’s Therapeutic Research Institute. She is part of the leadership of the Alzheimer’s Therapeutic Research Institute in San Diego. Her work is focused on the science of recruitment and retention of diverse participants into clinical trials. Currently, she works on evaluating strategies that promote participation of cognitively unimpaired, at-risk, diverse adults into studies that aim to help prevent the symptoms of Alzheimer’s well before they begin.
Michael S. Rafii, MD PhD
Michael S. Rafii, MD, PhD, is a Professor of Clinical Neurology at the Keck School of Medicine and Medical Director of the Alzheimer’s Therapeutic Research Institute (ATRI). His research focuses on developing treatments for Alzheimer’s disease, including its genetic form in individuals with Down syndrome. He is Principal Investigator for the NIH-funded Alzheimer’s Clinical Trials Consortium – Down Syndrome (ACTC-DS) and serves in leadership roles at ATRI and the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Robert Rissman, MD
Dr. Robert Rissman is a Professor of Physiology and Neuroscience, the W.M. Keck Endowed Professor in Medicine, and the founding Director of the Neuroscience Translational Research Division (NTRD) at ATRI. He leads the ATRI Biomarker Laboratory and Biorepository and serves as the ACTC Biorepository Unit Lead. His research focuses on biomarker discovery in Alzheimer's Disease (AD), aiming to understand how treatment parameters may impact these biomarkers.
Laurie Ryan, PhD
Dr. Laurie Ryan is Chief of the Clinical Interventions and Diagnostics Branch Division of Neuroscience at the National Institute on Aging, overseeing clinical research programs focused on Alzheimer's disease and related dementias. With a background in clinical neuropsychology, she previously worked at the Defense and Veterans Brain Injury Center (DVBIC) and became the Assistant Director for Research. Dr. Ryan joined the NIA in 2005 and has played a key role in Alzheimer’s clinical trials, eventually being promoted to the branch chief position in 2013.
Ronald Petersen, MD
Dr. Ronald C. Petersen, M.D., Ph.D., is a leading researcher in cognitive aging, focusing on conditions such as Alzheimer's, frontotemporal lobar degeneration, and Lewy body dementia. He directs both the Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging, where his team examines aging individuals over time using neuroimaging and biomarkers to understand cognitive changes and neurodegenerative disorders.
Marwan Sabbagh, MD
Dr. Marwan Sabbagh, M.D., is a behavioral neurologist and the Moreno Family Chair for Alzheimer's Research at the Barrow Neurological Institute. A specialist in Alzheimer's diagnosis and treatment, he also serves as the Vice Chair of Research at the Institute’s Department of Neurology. Dr. Sabbagh has led numerous national Alzheimer's prevention and treatment trials and serves as editor-in-chief of Neurology and Therapy. He has authored several books and contributed to numerous scientific articles.
Heather M. Snyder, PhD
Dr. Heather M. Snyder, Ph.D., is Senior Vice President for Medical & Scientific Relations at the Alzheimer’s Association. She oversees the association's global funding initiatives, including the International Research Grant Program. Dr. Snyder is also involved in strategic studies like the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). As a leading expert in the field, Snyder has been prominently featured in tv, print, and online mediums including The New York Times, The Washington Post and The Wall Street Journal.
Reisa A. Sperling, MD
Dr. Reisa Sperling is a neurologist at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital. She leads studies on Alzheimer's detection, including the A4 study, and led the NIA-Alzheimer’s Association workgroup to develop guidelines for “Preclinical Alzheimer’s disease.” Dr. Sperling was awarded the American Academy of Neurology Potamkin Prize and recognized as one of the 2017 Most Disruptive Women in Healthcare.
Arthur W. Toga, PhD
Dr. Toga focuses on neuroimaging algorithms, developing new visualization techniques and statistical measurements. His research includes creating 3D digital neuroanatomic atlases for precise localization and multisubject comparisons. His work involves local deformation methods to equate brain data from various subjects and modalities and the development of electronic databases for archiving and sharing brain data.
Bruno Vellas, MD, PhD
Dr. Bruno Vellas is the founder of Institut Hospitalier Universitaire (IHU) HealthAge in Toulouse. Vellas chairs the Gérontopôle & Department of Geriatric Internal Medicine, Alzheimer’s Disease Research and Clinical Center at the Toulouse University Hospital. He has been pivotal in the creation of major initiatives like European Alzheimer’s Disease Consortium (EADC), Clinical Trials on Alzheimer’s Disease (CTAD), and The Journal of Prevention of Alzheimer’s Disease (JPAD). He has authored over 500 publications, holds multiple leadership roles in international scientific advisory boards, and was elected to the French National Academy of Medicine in 2016.
Michael Weiner, MD
Dr. Michael Weiner is a Professor Emeritus at the University of California, San Francisco and the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI), the largest observational study on Alzheimer's disease. His research focuses on using MRI, PET, and biomarkers for diagnosing neurodegenerative diseases, particularly Alzheimer's. He has pioneered the use of magnetic resonance spectroscopy (MRS) in clinical applications and leads several initiatives to identify and monitor Alzheimer's disease progression.